Corbus Pharmaceuticals Holdings (CRBP) Receivables (2016 - 2021)

Corbus Pharmaceuticals Holdings' Receivables history runs 5 years deep, the most recent figure standing at $2.5 million for Q3 2021.

• On a quarterly basis, Receivables rose 160.39% year-over-year to $2.5 million in Q3 2021; TTM through Sep 2021 was $2.5 million, a 160.39% increase from a year earlier, with the FY2020 full-year figure at $1.6 million, down 39.64% from the prior year.
• Receivables held at $2.5 million in Q3 2021 per CRBP's latest filing, from $2.5 million in the prior quarter.
• Across five years, Receivables topped out at $4.4 million in Q1 2020 and bottomed at $500000.0 in Q3 2017.
• The 4-year median for Receivables is $2.5 million (2021), against an average of $2.2 million.
• Biggest YoY gain for Receivables was 160.39% in 2021; the steepest drop was 43.73% in 2021.
• Year by year, Receivables stood at $500000.0 in 2017, then soared by 436.21% to $2.7 million in 2019, then plunged by 39.64% to $1.6 million in 2020, then surged by 54.48% to $2.5 million in 2021.
• Per Business Quant, the three latest CRBP Receivables figures stand at $2.5 million (Q3 2021), $2.5 million (Q2 2021), and $2.5 million (Q1 2021).